Management of psoriasis vulgaris and multiple sclerosis with fumaric acid
Open accessAbstract
To the Editor: Psoriasis vulgaris has not only been associated with several comorbidities like metabolic syndrome and cardiovascular disease, but also with neurologic disorders like multiple sclerosis (MS).1 New-onset psoriatic lesions and exacerbations have been described after treatment with biologics for MS, mainly interferon-beta (INF-β) as well as with other biologics such as natalizumab.2 INF-β is the first-line treatment for clinically isolated syndrome with the high risk for MS development or for relapsing-remitting multiple sclerosis (RR-MS).
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Psoriasis vulgaris is biologically characterized by UPR.
“this finding is consistent with the alleviation of psoriasis vulgaris, also biologically characterized by UPR [455,456].”
From GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review (2022) · cites this paper as [455]
Cited by
Sorted by citations
De Masi, R., & Orlando, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137373 · Cited by 20 · see citing works
“In addition, this finding is consistent with the alleviation of psoriasis vulgaris, also biologically characterized by UPR [455,456].”
Result
- Authors
- Gkalpakiotis, S., Arenberger, P., Gkalpakioti, P., Meluzinova, E., Chandran, D., & Arenbergerova, M.
- Affiliations
- Charles University (CZ)
- Corresponding author
- Gkalpakiotis, Spyridon
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 70
- Issue
- 3
- Pages
- e60-e61
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W1974807352
- Cited by
- 8
- References
- 0
- Citations by year
- 2026: 1 · 2022: 1 · 2018: 1 · 2017: 1 · 2015: 3 · 2014: 1
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the American Academy of Dermatology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Keywords
- plaque psoriasis, multiple sclerosis, fumaric acid, interferon-beta, biologic therapy, relapsing-remitting multiple sclerosis, clinically isolated syndrome, psoriasis comorbidities, natalizumab, psoriasis exacerbation
- MeSH terms
- Administration, Oral, Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Fumarates, Humans, Multiple Sclerosis, Psoriasis, Severity of Illness Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
